ImmunityBio (IBRX)
(Delayed Data from NSDQ)
$3.60 USD
-0.12 (-3.23%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $3.60 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
F Value C Growth D Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$3.60 USD
-0.12 (-3.23%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $3.60 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
F Value C Growth D Momentum F VGM
Zacks News
Company News for Aug 13, 2024
by Zacks Equity Research
Companies in The News Are: GOLD,MNDY,IBRX,RNA
ImmunityBio (IBRX) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
ImmunityBio (IBRX) delivered earnings and revenue surprises of -17.65% and 58.54%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Quanterix Corporation (QTRX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Quanterix (QTRX) delivered earnings and revenue surprises of -8.70% and 0.56%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Dynavax Technologies (DVAX) Tops Q2 Earnings Estimates
by Zacks Equity Research
Dynavax Technologies (DVAX) delivered earnings and revenue surprises of 33.33% and 4.06%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Spero Therapeutics, Inc. (SPRO) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Spero Therapeutics (SPRO) delivered earnings and revenue surprises of 5.71% and 4.05%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Blueprint Medicines (BPMC) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Blueprint Medicines (BPMC) delivered earnings and revenue surprises of 37.50% and 32.14%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
ImmunityBio (IBRX) Gains 17% in the Past Week: Here's Why
by Zacks Equity Research
ImmunityBio (IBRX) rises 17% in the past week as it announces insurance coverage as well as the treatment of the first patients with its newly approved bladder cancer immunotherapy, Anktiva.
Here's Why ImmunityBio (IBRX) Is a Great 'Buy the Bottom' Stock Now
by Zacks Equity Research
After losing some value lately, a hammer chart pattern has been formed for ImmunityBio (IBRX), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
ImmunityBio (IBRX)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
Qiagen (QGEN) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Qiagen (QGEN) delivered earnings and revenue surprises of 2.04% and 0.94%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Should IQ Chaikin U.S. Small Cap ETF (CSML) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for CSML
FDA Rejects ImmunityBio's (IBRX) Bladder Cancer Therapy Filing
by Zacks Equity Research
FDA rejects ImmunityBio's (IBRX) filing seeking approval of Anktiva (N-803) as a combo-therapy in bladder cancer indication, citing deficiencies in an inspection of contract manufacturing firms.
ImmunityBio (IBRX) Stock Jumps 43.2%: Will It Continue to Soar?
by Zacks Equity Research
ImmunityBio (IBRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Moderna (MRNA) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Moderna (MRNA) delivered earnings and revenue surprises of 110.73% and 60.08%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
LAVA Therapeutics N.V. (LVTX) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
LAVA Therapeutics N.V. (LVTX) delivered earnings and revenue surprises of 49.18% and 53.20%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Spero Therapeutics, Inc. (SPRO) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Spero Therapeutics, Inc. (SPRO) delivered earnings and revenue surprises of 1.14% and 13.35%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Celldex Therapeutics (CLDX) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Celldex (CLDX) delivered earnings and revenue surprises of -34.88% and 53.43%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Pieris Pharmaceuticals (PIRS) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Pieris Pharmaceuticals (PIRS) delivered earnings and revenue surprises of -27.27% and 64.68%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Top COVID-19 Vaccine Stories of April Put Biotech ETFs in Focus
by Sweta Jaiswal, FRM
Let's take a look at some top coronavirus vaccine stories of April and the possible impact they can have on biotech ETFs.
ImmunityBio (IBRX) Reports Positive COVID-19 Vaccine Data
by Zacks Equity Research
ImmunityBio (IBRX) reports positive initial data on its COVID-19 vaccine candidate in healthy phase I study participants.